Bayer's Parkinson's cell therapy passes early clinical safety test, clearing path to phase 2

Bayer has early evidence that its Parkinson’s disease cell therapy is safe. Now, with a phase 2 clinical trial on course to open enrollment next year, the German drugmaker is set to start showing whether the candidate can undo damage and restore motor function.